By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Essen BioScience today said that it will provide ion channel screening services for Swiss drug firm Nycomed.

Ann Arbor, Mich.-based Essen said that the firms will collaborate on screening, optimizing, and developing modulators of voltage-gate ion channels for potential use as pain therapeutics. Essen said that it will contribute its expertise in ion channel drug discovery, planar array electrophysiology, and in vitro profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.